VGBR 04
Alternative Names: VGB-R04Latest Information Update: 28 Aug 2025
At a glance
- Originator Shanghai Vitalgen BioPharma
- Developer Chinese Academy of Medical Sciences; Shanghai Vitalgen BioPharma
- Class Antihaemorrhagics; Gene therapies
- Mechanism of Action Factor IX replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia B
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for clinical-Phase-Unknown development in Haemophilia-B in China (IV, Infusion)
- 06 Jul 2022 Clinical trials in Haemophilia B in China (IV), prior to July 2022 (Vitalgen BioPharma website, July 2022)
- 01 Jul 2022 Preclinical trials in Haemophilia B in China (IV), prior to July 2022 (Vitalgen BioPharma pipeline, July 2022)